1-[(3,5-dihydroxy)phenyl]octan-1-one | 1257228-28-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[(3,5-dihydroxy)phenyl]octan-1-one
• 英文别名: 1-(3,5-Dihydroxyphenyl)-1-octanone；1-(3,5-dihydroxyphenyl)octan-1-one
• CAS: 1257228-28-6
• 化学式: C₁₄H₂₀O₃
• 分子量: 236.311
• InChiKey: XUXIDIORIAAKIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-溴代庚烷 在 silica gel 、 三溴化硼 、 magnesium 、 pyridinium chlorochromate 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 31.75h， 生成 1-[(3,5-dihydroxy)phenyl]octan-1-one
  参考文献：
  名称：

  COMPOUNDS HAVING AGONISTIC EFFECT AGAINST GPR84, PREPARATION METHOD FOR COMPOUNDS AND USE OF COMPOUNDS

  摘要：

  本发明涉及一类由式I表示的化合物，或其药用可接受盐，其制备方法，以及作为GPR84激动剂的小分子工具的应用，以及它们在制备治疗败血症的药物中的应用。

  公开号：

  US20180237399A1

文献信息

• Monocyte modulation and control of tumor metastasis
  申请人：La Jolla Institute for Allergy and Immunology

  公开号：US11053297B2

  公开（公告）日：2021-07-06

  Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+ GR1− (Ly6C−)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1− (Ly6C−)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1− (Ly6C−)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1− (Ly6C−)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.

  本文公开了增加受试者肿瘤或癌症转移部位单核细胞数量的方法。非限制性实施方案包括给药或使用 Nur77 多肽或其子序列；Nur77 激动剂；CX3CR1 激动剂；CD14+ CD16+ 单核细胞和/或 CD14dimCD16+ (CD115+CD11b+ GR1- (Ly6C-))单核细胞；与 Nur77 激动剂接触或与 CX3CR1 激动剂接触的 CD14+ CD16+ 单核细胞和/或 CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-))单核细胞。本文还公开了增加、刺激、激活或促进单核细胞向受试者的肿瘤或癌症转移灶迁移或动员的方法。非限制性实施方案包括施用 Nur77 多肽或其子序列；Nur77 激动剂；CX3CR1 激动剂；CD14+ CD16+ 单核细胞和/或 CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-))单核细胞；或与 Nur77 激动剂接触或与 CX3CR1 激动剂接触的 CD14+ CD16+ 单核细胞和/或 CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-))单核细胞。
• METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE
  申请人：LA JOLLA INSTITUTE FOR ALLERGY AND IMMU

  公开号：US20130108602A1

  公开（公告）日：2013-05-02

  Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14 + CD16 + monocytes or CD14 dim CD16 + (CD115 + CD11b + GR1 − (Ly6C−)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.
• MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS
  申请人：La Jolla Institute for Allergy and Immunology

  公开号：US20210340218A1

  公开（公告）日：2021-11-04

  Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14 + CD16 + monocytes and/or CD14 dim CD16 + (CD115 + CD11b + GR1 − (Ly6C−)) monocytes; CD14 + CD16 + monocytes and/or CD14 dim CD16 + (CD115 + CD11b + GR1 − (Ly6C−)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14 + CD16 + monocytes and/or CD14 dim CD16 + (CD115 + CD11b + GR1 − (Ly6C−)) monocytes; or CD14 + CD16 + monocytes and/or CD14 dim CD16 + (CD115 + CD111b + GR1 − (Ly6C−)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.
• [EN] MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS<br/>[FR] MODULATION DES MONOCYTES ET SUPPRESSION DE LA MÉTASTASE TUMORALE
  申请人：LA JOLLA INST ALLERGY & IMMUNOLOGY

  公开号：WO2017075253A1

  公开（公告）日：2017-05-04

  Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1- (Ly6C-)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.